Pipeline
Driven by data and science, we apply our innovative TransCon technology platform to develop therapies that aim to address unmet medical needs. Below is an overview of our rare endocrine disease clinical development pipeline.
Endocrine Rare Diseases
|
Ascendis Programs
|
Clinical Trial
|
Phase
|
Location
|
|---|---|---|---|
|
Lonapegsomatropin-tcgd (TransCon hGH)
|
Turner Syndrome (children aged 1 to 10)
|
New InsiGHTS
NCT05690386 |
Phase 2
|
United States
|
Multi-Indication (children aged 2 to 17)
Turner syndrome, Idiopathic Short Stature (ISS), SHOX Deficiency, and Small for Gestational Age (SGA) |
HighLiGHts
NCT07221851 |
Phase 3
|
Multinational
|
|
Palopegteriparatide (TransCon PTH)
|
Hypoparathyroidism (adults)
|
PaTHway60
NCT07081997 |
Phase 3
|
United States
|
|
Navepegritide (TransCon CNP)
|
Achondroplasia (children and adolescents)
|
AttaCH
NCT05929807 |
Phase 2
|
Multinational
|
Achondroplasia (infants aged 0 to 2)
|
reACHin
NCT06079398 |
Phase 2
|
Multinational
|
Achondroplasia (adolescents aged 12 to 18)
|
teACH
NCT06732895 |
Phase 2
|
Multinational
|
|
Navepegritide + Lonapegsomatropin-tcgd
|
Achondroplasia (children aged 2 to 11)
|
COACH
NCT06433557 |
Phase 2
|
Multinational
|
TransCon product candidates are also in development in other indications and countries through strategic partnerships.
This section includes pipeline drug candidates currently undergoing clinical testing that may not be FDA-approved and therefore safety and efficacy have not been established. There is no guarantee that pipeline products or investigational uses will obtain FDA approval. This information is current as of 08/26.
